17 results
To prove the clinical feasibility of palliative whole brain radiotherapy without using a thermoplastic mask. Clinical feasibility in this study is defined when more than 70% of the patients can complete the radiation treatment without a mask. We…
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
We propose to conduct a randomised phase III trial evaluating a maintenance strategy comparing hepatic arterial injection of Yttrium-90 resin microspheres plus continuing simplified chemotherapy with/without targeted therapy (bevacizumab, or…
The primary aim of this study is to determine the added value of third look DLS to detect PM at a clinically occult stage following a negative second look DLS.
To develop a model system and infrastructure to individualize the treatment of patients with advanced pancreatic adenocarcinoma. Additionally, we aim to identify predictors of therapy (non)response.
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable CRLM (<=3cm) and no extrahepatic disease.
Main Objective (EudraCT):To evaluate the safety and tolerability of RO7198457 when administered as a single agent (Phase [Ph] Ia) or in combination with atezolizumab (Ph Ib), with or without prophylactic treatment with corticosteroids, including…
Primary ObjectivesThe primary objectives of this study are:Phase I, Part A - Dose Escalation:• To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CB-103 as a single agent when administered orally and with repeat…
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
To compare overall survival (OS) of patients with metastatic (Stage IV) PDAC treated with BBI-608 plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine.
To prospectively explore the feasibility safety, tolerability, preliminary efficacy, costs, and pharmacokinetic profile of repetitive ePIPAC-OX as a palliative monotherapy for isolated unresectable colorectal PM under controlled circumstances.
The main aim of this study is to determine the diagnostic accuracy of contrast-enhanced diffusion-weighted MRI (CE-DW-MRI) in the detection of liver metastases in patients with pancreatic cancer compared to a reference standard of histopathology and…
To determine local control of SBRT treatment for abdominopelvic oligometastasis based on a fractionation scheme of 45 Gy in 5 fractions, to evaluate local control, survival and toxicity. Use of the plan of the day as a tool for optimize tumor…
Primary objectives: To assess the feasibility, accuracy and safety of preoperative SPECT/CT and intraoperative fluorescence imaging after administration of 111In-labetuzumab-IRDye800CW in patients with PC of colorectal origin who will undergo…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
The aim of this research is to compare the effectiveness and cost-effectiveness of thermal ablation versus liver resection surgery in high surgical risk patients eligible for liver resection.
To assess the safety and feasibility of HIPEC and CS in Western patients with peritoneal metastases of gastric cancer, in terms of morbidity and mortality. Secondary objective is to determine the effect on survival and recurrence.